Cargando…

Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer

PURPOSE: This study investigated the clinical impact of pretreatment neutrophil-to-lymphocyte ratio (NLR) on survival in patients with oligometastatic breast cancer. PATIENTS AND METHODS: We collected data from 397 patients who underwent primary breast surgery from 2004 to 2015 and developed recurre...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Yuka, Fujishima, Makoto, Ono, Makiko, Masuda, Jun, Ozaki, Yukinori, Maeda, Tetsuyo, Uehiro, Natsue, Takahashi, Yoko, Kobayashi, Takayuki, Sakai, Takehiko, Osako, Tomo, Ueno, Takayuki, Ohno, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581831/
https://www.ncbi.nlm.nih.gov/pubmed/36153381
http://dx.doi.org/10.1007/s10549-022-06726-w
_version_ 1784812715946016768
author Inoue, Yuka
Fujishima, Makoto
Ono, Makiko
Masuda, Jun
Ozaki, Yukinori
Maeda, Tetsuyo
Uehiro, Natsue
Takahashi, Yoko
Kobayashi, Takayuki
Sakai, Takehiko
Osako, Tomo
Ueno, Takayuki
Ohno, Shinji
author_facet Inoue, Yuka
Fujishima, Makoto
Ono, Makiko
Masuda, Jun
Ozaki, Yukinori
Maeda, Tetsuyo
Uehiro, Natsue
Takahashi, Yoko
Kobayashi, Takayuki
Sakai, Takehiko
Osako, Tomo
Ueno, Takayuki
Ohno, Shinji
author_sort Inoue, Yuka
collection PubMed
description PURPOSE: This study investigated the clinical impact of pretreatment neutrophil-to-lymphocyte ratio (NLR) on survival in patients with oligometastatic breast cancer. PATIENTS AND METHODS: We collected data from 397 patients who underwent primary breast surgery from 2004 to 2015 and developed recurrence during the follow-up. We reviewed the images and clinical information and defined OMD according to the European Society for Medical Oncology advanced breast cancer guidelines. The NLR was calculated using pretreatment data of primary breast cancer. The cutoff value of the NLR was determined by receiver operating characteristic curve with Youden Index. RESULTS: Among 397 patients, 131 had OMD at recurrence. The low-NLR group included patients of significantly older age at primary cancer than those in the high-NLR group. A low NLR indicated a better overall survival (p = 0.023) after adjusting for relevant factors, including estrogen receptor status, surgical resection of metastatic disease, metastatic organ number, disease-free interval, and liver metastasis than did the high-NLR group. We developed prognostic models for OMD using six independent prognostic factors, including the NLR. The number of factors was associated with overall survival; patients with all six favorable factors showed a good overall survival of 90.9% at 8 years and those with four or more factors showed 70.4%. CONCLUSIONS: The NLR was an independent prognostic factor for overall survival in OMD. The number of favorable prognostic factors was associated with overall survival. A prognostic model, including the NLR, will help identify patients with a favorable prognosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10549-022-06726-w.
format Online
Article
Text
id pubmed-9581831
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-95818312022-10-21 Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer Inoue, Yuka Fujishima, Makoto Ono, Makiko Masuda, Jun Ozaki, Yukinori Maeda, Tetsuyo Uehiro, Natsue Takahashi, Yoko Kobayashi, Takayuki Sakai, Takehiko Osako, Tomo Ueno, Takayuki Ohno, Shinji Breast Cancer Res Treat Clinical Trial PURPOSE: This study investigated the clinical impact of pretreatment neutrophil-to-lymphocyte ratio (NLR) on survival in patients with oligometastatic breast cancer. PATIENTS AND METHODS: We collected data from 397 patients who underwent primary breast surgery from 2004 to 2015 and developed recurrence during the follow-up. We reviewed the images and clinical information and defined OMD according to the European Society for Medical Oncology advanced breast cancer guidelines. The NLR was calculated using pretreatment data of primary breast cancer. The cutoff value of the NLR was determined by receiver operating characteristic curve with Youden Index. RESULTS: Among 397 patients, 131 had OMD at recurrence. The low-NLR group included patients of significantly older age at primary cancer than those in the high-NLR group. A low NLR indicated a better overall survival (p = 0.023) after adjusting for relevant factors, including estrogen receptor status, surgical resection of metastatic disease, metastatic organ number, disease-free interval, and liver metastasis than did the high-NLR group. We developed prognostic models for OMD using six independent prognostic factors, including the NLR. The number of factors was associated with overall survival; patients with all six favorable factors showed a good overall survival of 90.9% at 8 years and those with four or more factors showed 70.4%. CONCLUSIONS: The NLR was an independent prognostic factor for overall survival in OMD. The number of favorable prognostic factors was associated with overall survival. A prognostic model, including the NLR, will help identify patients with a favorable prognosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10549-022-06726-w. Springer US 2022-09-24 2022 /pmc/articles/PMC9581831/ /pubmed/36153381 http://dx.doi.org/10.1007/s10549-022-06726-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Clinical Trial
Inoue, Yuka
Fujishima, Makoto
Ono, Makiko
Masuda, Jun
Ozaki, Yukinori
Maeda, Tetsuyo
Uehiro, Natsue
Takahashi, Yoko
Kobayashi, Takayuki
Sakai, Takehiko
Osako, Tomo
Ueno, Takayuki
Ohno, Shinji
Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer
title Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer
title_full Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer
title_fullStr Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer
title_full_unstemmed Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer
title_short Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer
title_sort clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer
topic Clinical Trial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581831/
https://www.ncbi.nlm.nih.gov/pubmed/36153381
http://dx.doi.org/10.1007/s10549-022-06726-w
work_keys_str_mv AT inoueyuka clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer
AT fujishimamakoto clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer
AT onomakiko clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer
AT masudajun clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer
AT ozakiyukinori clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer
AT maedatetsuyo clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer
AT uehironatsue clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer
AT takahashiyoko clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer
AT kobayashitakayuki clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer
AT sakaitakehiko clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer
AT osakotomo clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer
AT uenotakayuki clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer
AT ohnoshinji clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer